212 related articles for article (PubMed ID: 21439833)
1. Introduction of aromatic group on 4'-OH of α-GalCer manipulated NKT cell cytokine production.
Zhang W; Xia C; Nadas J; Chen W; Gu L; Wang PG
Bioorg Med Chem; 2011 Apr; 19(8):2767-76. PubMed ID: 21439833
[TBL] [Abstract][Full Text] [Related]
2. Induction of Th1-biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells.
Tashiro T; Sekine-Kondo E; Shigeura T; Nakagawa R; Inoue S; Omori-Miyake M; Chiba T; Hongo N; Fujii S; Shimizu K; Yoshiga Y; Sumida T; Mori K; Watarai H; Taniguchi M
Int Immunol; 2010 Apr; 22(4):319-28. PubMed ID: 20181652
[TBL] [Abstract][Full Text] [Related]
3. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
4. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P
J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288
[TBL] [Abstract][Full Text] [Related]
5. 6'-derivatised alpha-GalCer analogues capable of inducing strong CD1d-mediated Th1-biased NKT cell responses in mice.
Trappeniers M; Van Beneden K; Decruy T; Hillaert U; Linclau B; Elewaut D; Van Calenbergh S
J Am Chem Soc; 2008 Dec; 130(49):16468-9. PubMed ID: 19554718
[No Abstract] [Full Text] [Related]
6. NKT TCR recognition of CD1d-α-C-galactosylceramide.
Patel O; Cameron G; Pellicci DG; Liu Z; Byun HS; Beddoe T; McCluskey J; Franck RW; Castaño AR; Harrak Y; Llebaria A; Bittman R; Porcelli SA; Godfrey DI; Rossjohn J
J Immunol; 2011 Nov; 187(9):4705-13. PubMed ID: 21964029
[TBL] [Abstract][Full Text] [Related]
7. Species-specific activity of glycolipid ligands for invariant NKT cells.
Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
[TBL] [Abstract][Full Text] [Related]
8. NKT and tolerance.
Diana J; Beaudoin L; Gautron AS; Lehuen A
Methods Mol Biol; 2011; 677():193-206. PubMed ID: 20941612
[TBL] [Abstract][Full Text] [Related]
9. NKT cell responses to glycolipid activation.
Tefit JN; Davies G; Serra V
Methods Mol Biol; 2010; 626():149-67. PubMed ID: 20099127
[TBL] [Abstract][Full Text] [Related]
10. 3-fluoro- and 3,3-difluoro-3,4-dideoxy-KRN7000 analogues as new potent immunostimulator agents: total synthesis and biological evaluation in human invariant natural killer T cells and mice.
Hunault J; Diswall M; Frison JC; Blot V; Rocher J; Marionneau-Lambot S; Oullier T; Douillard JY; Guillarme S; Saluzzo C; Dujardin G; Jacquemin D; Graton J; Le Questel JY; Evain M; Lebreton J; Dubreuil D; Le Pendu J; Pipelier M
J Med Chem; 2012 Feb; 55(3):1227-41. PubMed ID: 22243602
[TBL] [Abstract][Full Text] [Related]
11. Human and mouse type I natural killer T cell antigen receptors exhibit different fine specificities for CD1d-antigen complex.
Wun KS; Ross F; Patel O; Besra GS; Porcelli SA; Richardson SK; Keshipeddy S; Howell AR; Godfrey DI; Rossjohn J
J Biol Chem; 2012 Nov; 287(46):39139-48. PubMed ID: 22995911
[TBL] [Abstract][Full Text] [Related]
12. 4,5-cis unsaturated α-GalCer analogues distinctly lead to CD1d-mediated Th1-biased NKT cell responses.
Cui Y; Li Z; Cheng Z; Xia C; Zhang Y
Chem Res Toxicol; 2015 Jun; 28(6):1209-15. PubMed ID: 25955524
[TBL] [Abstract][Full Text] [Related]
13. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
[TBL] [Abstract][Full Text] [Related]
14. Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.
Biburger M; Tiegs G
J Leukoc Biol; 2008 Jul; 84(1):264-79. PubMed ID: 18407967
[TBL] [Abstract][Full Text] [Related]
15. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of Bz amide-containing α-GalCer derivatives as natural killer T cell modulators.
Kishi J; Inuki S; Hirata N; Kashiwabara E; Yoshidome D; Ichihara O; Fujimoto Y
Bioorg Med Chem Lett; 2019 Apr; 29(8):970-973. PubMed ID: 30824201
[TBL] [Abstract][Full Text] [Related]
17. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
[TBL] [Abstract][Full Text] [Related]
18. Identification of canine natural CD3-positive T cells expressing an invariant T-cell receptor alpha chain.
Yasuda N; Masuda K; Tsukui T; Teng A; Ishii Y
Vet Immunol Immunopathol; 2009 Dec; 132(2-4):224-31. PubMed ID: 19748683
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of acyl-chain- and galactose-6''-modified analogues of α-GalCer for NKT cell activation.
Hsieh MH; Hung JT; Liw YW; Lu YJ; Wong CH; Yu AL; Liang PH
Chembiochem; 2012 Jul; 13(11):1689-97. PubMed ID: 22730199
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
Berkers CR; Ovaa H
Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
